<DOC>
	<DOCNO>NCT02038296</DOCNO>
	<brief_summary>To evaluate local tumor control survival rate repeat transarterial chemoembolization ( TACE ) use three different protocol hepatocellular carcinoma ( HCC ) patient .</brief_summary>
	<brief_title>Different Protocols Repeated Transarterial Chemoembolization Treatment Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Patients histologically confirm HCC unresectable disease without extrahepatic metastasis ; HCC previous treatment ; age 18 75 year ; Life expectancy least 8 week ; main tumor size great 5 cm ; adequate hematologic function ( platelet count : &gt; 60 × 109 platelets/L ; hemoglobin : &gt; 90g/L ; prothrombin time : &lt; 3 second control ) ; adequate renal function ( serum creatinine : ≤1.5 × upper limit normal ) ; ChildPugh classification A B grade ; Barcelona Clinic Liver Cancer ( BCLC ) stage B C ; Eastern Cooperative Group performance status zero one . hypovascular tumor ( defined tumor part less contrastenhanced nontumorous liver parenchyma arterial phase compute tomography scan ) ; diffusetype HCC ; evidence hepatic decompensation include esophageal gastric variceal bleed hepatic encephalopathy ; severe underlie cardiac renal disease ; color Doppler ultrasonography show portal vein tumor thrombosis complete main portal vein obstruction without cavernous transformation ; obstructive jaundice .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Transarterial chemoembolization</keyword>
	<keyword>Gemcitabine</keyword>
</DOC>